Interim Report For FluoGuide, Second Quarter 2019
FluoGuide today publishes its interim report for the period January - June 2019Andreas Kjær, responsible for research of FluoGuide comments: "I am very pleased that promising data on the benefit of FG001 in glioblastoma and pancreatic cancer have been selected for presentation at WMIC, an important society within molecular imaging and surgical guidance. Optical targeting of uPAR is likely to become of benefit to patients and surgeons in several cancer indications and this presentation is an important event to highlight the technology’s potential." Morten Albrechtsen, CEO of FluoGuide